世界のオリゴヌクレオチド合成市場(~2026年):製品別(薬剤、合成オリゴ(プライマー、プローブ)、試薬)、種類別(カスタム、プレデザイン)、用途別(治療(ASO、siRNA)、研究(PCR)、診断)、エンドユーザー別(病院、製薬、CRO)

◆英語タイトル:Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026
◆商品コード:BT2680
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2029年4月15日
◆ページ数:237
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は、世界のオリゴヌクレオチド合成市場規模が2021年63億ドルから2026年141億ドルまで、年平均17.6%成長すると予測しています。本調査レポートでは、オリゴヌクレオチド合成の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(オリゴヌクレオチドベース薬剤、合成オリゴヌクレオチド、試薬、機器)分析、用途別(治療、診断、研究)分析、種類別(カスタム、プレデザイン)分析、エンドユーザー別(病院、製薬&バイオテクノロジー、診断研究所、医薬品開発業務受託機関&医薬品製造受託機関(CRO&CMO)、学術研究機関)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のオリゴヌクレオチド合成市場規模:製品別(オリゴヌクレオチドベース薬剤、合成オリゴヌクレオチド、試薬、機器)
・世界のオリゴヌクレオチド合成市場規模:用途別(治療、診断、研究)
・世界のオリゴヌクレオチド合成市場規模:種類別(カスタム、プレデザイン)
・世界のオリゴヌクレオチド合成市場規模:エンドユーザー別(病院、製薬&バイオテクノロジー、診断研究所、医薬品開発業務受託機関&医薬品製造受託機関(CRO&CMO)、学術研究機関)
・世界のオリゴヌクレオチド合成市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period.”
The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

“By synthesized oligos product segment, the primers segmentaccounted for the fastest growing segment of theoligonucleotide synthesis market”
Based on product, the oligonucleotide synthesis market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. In 2020, the primers segment accounted for the fastest growing segment of this market, as they are used in various applications such as PCR, sequencing, gene synthesis, and cloning applications, among others.

“By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of theoligonucleotide synthesis market”
Based on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. The therapeutic application segment is further segmented into Antisense oligonucleotide-based therapies, siRNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. IN 2020, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

“Asia Pacific: The fastest-growing region in the oligonucleotide synthesismarket.”
The oligonucleotide synthesis market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.

“North America: the largest share of the oligonucleotide synthesismarket”
North America accounted for the largest market share. The large share of this region can be attributed to the increasing R&D in life sciences, rising focus on improving the safety & quality of healthcare, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of many global players in this region is another key factor contributing to the large share of this market segment.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— CXOs- 20%, Executives – 25%, Mangers – 55%
• By Region— North America – 30%, Europe – 20%, APAC – 40%, RoW- 10%

The oligonucleotide synthesis market is dominated by a few globally established players such as Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Eurofins Scientific (Germany),Maravai Lifesciences (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Microsynth AG (Switzerland), PolyGen GmbH (Germany), Metabion International AG (Germany), CSBio (US), TAG Copenhagen A/S (Denmark), Biolytic Lab Performance Inc. (US), Gene Link (US), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), Jazz Pharmaceuticals, Inc. (US) Dynavax Technologies (US), and Alnylam Pharmaceuticals, Inc. (US).

Research Coverage:
The report segments the oligonucleotide synthesismarket based on region (Asia Pacific, Europe, North America, Latin America and Middle East and Africa), product(oligonucleotide-based drugs,
Synthesized oligonucleotides, reagents, and equipment), application(therapeutic, research and diagnostic), and end user (hospitals, pharmaceutical & biotechnology companies, academic research centers, diagnostic laboratories, and CROs and CMOs). The report also provides a comprehensive review of market drivers, restraints opportunities, challenges and trends in the oligonucleotide synthesismarket.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the oligonucleotide synthesismarket and provides them information on key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

12 COMPANY PROFILES 196
12.1 MAJOR PLAYERS 196
(Business Overview, Products/Solutions Offered, Recent Developments, Right to Win)*
12.1.1 DANAHER CORPORATION 196
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 197
12.1.2 THERMO FISHER SCIENTIFIC, INC. 201
FIGURE 30 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 201
12.1.3 MERCK KGAA 204
FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2020) 205
12.1.4 EUROFINS SCIENTIFIC 207
FIGURE 32 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020) 208
12.1.5 LGC LIMITED 209
FIGURE 33 LGC LIMITED: COMPANY SNAPSHOT (2020) 210
12.1.6 MARAVAI LIFESCIENCES 213
FIGURE 34 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2020) 214
12.1.7 AGILENT TECHNOLOGIES, INC. 216
FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 217
12.1.8 KANEKA CORPORATION 219
FIGURE 36 KANEKA CORPORATION: COMPANY SNAPSHOT (2019) 219
12.1.9 BIOLEGIO B.V. 222
12.1.10 BIOLYTIC LAB PERFORMANCE INC. 223
12.1.11 MICROSYNTH AG 224
12.2 OTHER PLAYERS 226
12.2.1 ADTBIO LTD. 226
12.2.2 TWIST BIOSCIENCE CORPORATION 226
12.2.3 ETON BIOSCIENCE, INC. 227
12.2.4 CSBIO 227
12.2.5 TAG COPENHAGEN A/S 228
12.3 THERAPEUTIC PLAYERS 229
12.3.1 BIOGEN INC. 229
FIGURE 37 BIOGEN: COMPANY SNAPSHOT (2020) 230
12.3.2 SAREPTA THERAPEUTICS, INC. 232
FIGURE 38 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2020) 232
12.3.3 IONIS PHARMACEUTICALS, INC. 234
FIGURE 39 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2020) 235
12.3.4 ALNYLAM PHARMACEUTICALS, INC. 237
FIGURE 40 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2020) 238
*Business Overview, Products/Solutions Offered, Recent Developments, Right to Win might not be captured in case of unlisted companies.

13 APPENDIX 240
13.1 DISCUSSION GUIDE 240
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 243
13.3 AVAILABLE CUSTOMIZATIONS 245
13.4 RELATED REPORTS 245
13.5 AUTHOR DETAILS 246

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のオリゴヌクレオチド合成市場(~2026年):製品別(薬剤、合成オリゴ(プライマー、プローブ)、試薬)、種類別(カスタム、プレデザイン)、用途別(治療(ASO、siRNA)、研究(PCR)、診断)、エンドユーザー別(病院、製薬、CRO)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆